Atossa wins U.S. patent related to multiple formulation of lead asset

JLGutierrez Atossa Therapeutics ( NASDAQ: ATOS ) on Wednesday announced the issuance of a U.S. patent related to various oral formulations comprising its lead asset, (Z)-endoxifen as well as methods of using those formulations.

U.S. Patent No.



12,281,056 covers as many as 58 claims related to (Z)-endoxifen.